Long-Term Liabilities: The sum of all non-current liabilities.
Myriad Genetics, Inc. (MYGN) had Long-Term Liabilities of $204.30M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$190.70M |
|
$-43.20M |
|
$63.70M |
|
$127.00M |
|
$229.60M |
|
$-38.90M |
|
$-3.70M |
|
$-42.60M |
|
$-42.60M |
|
$-43.20M |
|
$-43.20M |
|
$-43.20M |
|
$-43.20M |
|
$-38.90M |
|
$-26.40M |
|
94.80M |
|
94.80M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$289.00M |
|
$108.90M |
|
$349.90M |
|
$638.90M |
|
$130.70M |
|
$120.70M |
|
|
Long-Term Liabilities |
$204.30M |
$335.00M |
|
$303.90M |
|
$117.80M |
|
$303.90M |
|
95.60M |
|
| Cash Flow Statement Financials | |
$-24.00M |
|
$-9.70M |
|
$-0.80M |
|
$151.30M |
|
$116.80M |
|
$-34.50M |
|
$13.70M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.21 |
|
-- |
|
-- |
|
0.28 |
|
0.40 |
|
66.60% |
|
-20.40% |
|
-20.40% |
|
-- |
|
-22.34% |
|
-22.65% |
|
$-31.50M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
2.08 |
|
1.74 |
|
51.68 |
|
-14.22% |
|
-36.67% |
|
-6.76% |
|
-10.17% |
|
$3.18 |
|
$-0.33 |
|
$-0.25 |
|